Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche’s Pipeline Prospects Promise Steady Sailing To More Growth

Executive Summary

Analysts increasingly see Roche’s pipeline and newly launched drugs winning over investors and neutralizing worries over biosimilars and potential US pricing reforms. Its 16 September pipeline update in London may reinforce that.

You may also be interested in...



Roche Ups Outlook, Sees Spark Buy By Year-End

Roche presented another strong quarterly performance and raised its outlook again for the full year, as sales continued to be driven in the third quarter by its portfolio of new medicines. It still believes its delayed takeover of Spark Therapeutics will happen by year-end.  

Deal Watch: BMS To Tap Early-Stage Breakthroughs In Partnership With BioMotiv

Bristol-Myers Squibb will partner with the biotech accelerator to fund and launch biotechs, with the pharma getting an option to buy. Novartis signs another agreement with IFM months after buying its IFM Tre affiliate.

Roche's New Chief Medical Officer Levi Garraway Brings Deep Cancer Genomics Expertise

CMO Sandra Horning will retire at the end of the year, to be succeeded by Lilly's former senior VP of oncology R&D on 1 October.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel